The effect of sex and gender on diabetic complications

Current Diabetes Reviews

Volumn 12, Issue , 2016, Pages

  Seghieri, Giuseppe ^a,b   Policardo, Laura ^a,b   Anichini, Roberto ^c   Franconi, Flavia ^d   Campesi, Ilaria ^d   Cherchi, Sara ^e   Tonolo, Giancarlo ^e  

^a Epidemiology Unit   (Italy)

^b Section Dermatology   (Italy)

^c Division of Urology   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e UODiabetologia ASL 2   (Italy)

Author keywords

Adverse drug reactions; Diabetes; Diabetic macroangiopathy; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Sex gender differences

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; VASCULAR DISEASE; ANIMAL; DIABETIC COMPLICATION; RISK FACTOR; SEXUAL CHARACTERISTICS;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; RISK FACTORS; SEX CHARACTERISTICS;

EID: 85007595547     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399812666160517115756     Document Type: Review

References (166)

1. Marino M, Masella R, Bulzomi P et al. Nutrition and human health from a sex-gender perspective. Mol Aspects Med. 2011;32(1):1-70.
2. Hu G. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608-17.
3. Regensteiner JG, Golden S, Huebschmann AG et al. Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2015;132(25):2424-47.
4. Rossi MC, Cristofaro MR, Gentile S et al. Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the AMD Annals initiative. Diabetes Care. 2013;36(10):3162-8.
5. Howard BV, Cowan LD, Go O et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care. 1998;21(8):1258-65.
6. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care. 1998;21(8):1236-9.
7. Policardo L, Seghieri G, Francesconi P et al. Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke. J Diabetes Complications. 2015;29(5):713-7.
8. Lewis EJ, Hunsicker LG, Rodby RA. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis. 2001;38(4 Suppl 1):S191-4.
9. Walker EA, Molitch M, Kramer MK et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006;29(9):1997-2002.
10. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8-13.
11. Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760-5.
12. Soedamah-Muthu SS, Chaturvedi N, Toeller M et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004;27(2):530-7.
13. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: metaanalysis of 37 prospective cohort studies. Bmj. 2006;332(7533):73-8.
14. Norhammar A, Schenck-Gustafsson K. Type 2 diabetes and cardiovascular disease in women. Diabetologia. 2013;56(1):1-9.
15. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014;383(9933):1973-80.
16. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998;158(6):617-21.
17. Steinberg HO, Paradisi G, Cronin J et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation. 2000;101(17):2040-6.
18. Koh KK, Kang MH, Jin DK et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol. 2001;38(5):1409-15.
19. Meyer MR, Clegg DJ, Prossnitz ER, Barton M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf). 2011;203(1):259-69.
20. Rautio A, Lundberg V, Messner T et al. Favourable trends in the incidence and outcome of myocardial infarction in nondiabetic, but not in diabetic, subjects: findings from the MONICA myocardial infarction registry in northern Sweden in 1989-2000. J Intern Med. 2005;258(4):369-77.
21. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-6.
22. Pilote L, Dasgupta K, Guru V et al. A comprehensive view of sexspecific issues related to cardiovascular disease. Cmaj. 2007;176(6):S1-44.
23. Seghieri C, Francesconi P, Cipriani S et al. Gender effect on the relation between diabetes and hospitalization for heart failure. Exp Clin Endocrinol Diabetes. 2011;120(1):51-5.
24. Venskutonyte L, Malmberg K, Norhammar A, Wedel H, Ryden L. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. J Intern Med. 2010;268(1):75-82.
25. Reeves MJ, Bushnell CD, Howard G et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915-26.
26. Lewsey JD, Gillies M, Jhund PS et al. Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. Stroke. 2009;40(4):1038-43.
27. Eriksson M, Glader EL, Norrving B, Terent A, Stegmayr B. Sex differences in stroke care and outcome in the Swedish national quality register for stroke care. Stroke. 2009;40(3):909-14.
28. Seghieri G, Policardo L, Anichini R, Francesconi P. Gender difference in diabetes related excess risk of cardiovascular events: When does the ‘risk window’ open? Diabetologia 2015; 58 (Suppl 1):S134.
29. Chatterjee S, Peters SA, Woodward M et al. Type 2 Diabetes as a risk factor for dementia in women compared with men: A pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300-7.
30. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003;26(8):2335-40.
31. Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829-34.
32. Williams JW, Zimmet PZ, Shaw JE et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med. 2003;20(11):915-20.
33. DECODE Study Group. Age-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26(1):61-9.
34. Sicree RA, Zimmet PZ, Dunstan DW et al. Differences in height explain gender differences in the response to the oral glucose tolerance test-the AusDiab study. Diabet Med. 2008;25(3):296-302.
35. Anderwald C, Gastaldelli A, Tura A et al. Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. J Clin Endocrinol Metab. 2011;96(2):515-24.
36. Cavalot F, Petrelli A, Traversa M,et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus,particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91(3):813-19.
37. Wannamethee SG, Papacosta O, Lawlor DA et al. Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia. 2012;55(1):80-7.
38. Peters SA, Huxley RR, Sattar N, Woodward M. Sex Differences in the Excess Risk of Cardiovascular Diseases ssociated with Type 2 Diabetes: Potential Explanations and Clinical Implications. Curr Cardiovasc Risk Rep. 2015;9(7):36.
39. Legato MJ, Gelzer A, Goland R et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med. 2006;3(2):131-58.
40. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
41. Juutilainen A, Kortelainen S, Lehto S et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004;27(12):2898-904.
42. Franklin SS. Definition and epidemiology of hypertensive cardiovascular disease in women: the size of the problem. J Hypertens Suppl. 2002;20(2):S3-5.
43. Cipollini F, Arcangeli E, Greco E et al. Gender difference in the relation blood pressure-left ventricular mass and geometry in newly diagnosed arterial hypertension. Blood Press. 2012;21(4):255-64.
44. Glynn RJ, L’Italien GJ, Sesso HD, Jackson EA, Buring JE. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension. 2002;39(1):105-10.
45. Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E, Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med. 1984;311(15):953-9.
46. Chan P, Pan WH. Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabet Med. 1995;12(6):504-7.
47. Vina J, Gambini J, Lopez-Grueso R, Abdelaziz KM, Jove M, Borras C. Females live longer than males: role of oxidative stress. Curr Pharm Des. 2011; 1;17(36): 3959-65
48. Janand-Delenne B, Savin B, Habib G et al. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care. 1999;22(9):1396-400.
49. Lisabeth LD, Brown DL, Hughes R, Majersik JJ, Morgenstern LB. Acute stroke symptoms: comparing women and men. Stroke. 2009;40(6):2031-6.
50. Herlitz J, Dellborg M, Karlsson T et al. Treatment and outcome in acute myocardial infarction in a community in relation to gender. Int J Cardiol. 2009;135(3):315-22.
51. Reid JM, Dai D, Gubitz GJ et al. Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital. Stroke. 2008;39(4):1090-5.
52. Silander K, Alanne M, Kristiansson K et al. Gender differences in genetic risk profiles for cardiovascular disease. PLoS One. 2008;3(10):e3615.
53. Rautio A, Eliasson M, Stegmayr B. Favorable trends in the incidence and outcome in stroke in nondiabetic and diabetic subjects: findings from the Northern Sweden MONICA Stroke Registry in 1985 to 2003. Stroke. 2008;39(12):3137-44.
54. Icks A, Claessen H, Morbach S, Glaeske G, Hoffmann F. Timedependent impact of diabetes on mortality in patients with stroke: survival up to 5 years in a health insurance population cohort in Germany. Diabetes Care. 2012;35(9):1868-75.
55. Policardo L, Seghieri G, Anichini R et al. Effect of diabetes on hospitalization for ischemic stroke and related in-hospital mortality: a study in Tuscany, Italy, over years 2004-2011. Diabetes Metab Res Rev. 2015;31(3):280-6.
56. Faerch K, Carstensen B, Almdal TP, Jorgensen ME. Improved survival among patients with complicated type 2 diabetes in Denmark: A prospective study (2002-2010). J Clin Endocrinol Metab. 2014:jc20133210.
57. Franzini L, Ardigo D, Cavalot F et al. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis. 2013;23(3):235-41.
58. Abbate R, Mannucci E, Cioni G, Fatini C, Marcucci R. Diabetes and sex: from pathophysiology to personalized medicine. Intern Emerg Med. 2012;7 Suppl 3:S215-9.
59. Ferrara A, Mangione CM, Kim C et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care. 2008;31(1):69-74.
60. Fremont AM, Correa-de-Araujo R, Hayes SN. Gender disparities in managed care: it’s time for action. Womens Health Issues. 2007;17(3):116-9.
61. Vaccaro O, Boemi M, Cavalot F et al. The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. Atherosclerosis. 2008;198(2):396-402.
62. Lenzen MJ, Rosengren A, Scholte op Reimer WJ et al. Management of patients with heart failure in clinical practice: differences between men and women. Heart. 2008;94(3):e10.
63. Azevedo A. Gender differences in heart failure. Heart. 2008;94(3):264-5.
64. Seghieri C, Policardo L, Francesconi P, Seghieri G. Gender differences in the relationship between diabetes process of care indicators and cardiovascular outcomes. Eur J Public Health. 2015;26(2):219-24.
65. Anichini R, Cosimi S, Di Carlo A et al. Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab Syndr Obes. 2013;6:123-9.
66. Trout KK, Rickels MR, Schutta MH et al. Menstrual cycle effects on insulin sensitivity in women with type 1 diabetes: a pilot study. Diabetes Technol Ther. 2007;9(2):176-82.
67. Jovanovic L. Sex differences in insulin dose and postprandial glucose as BMI increases in patients with type 2 diabetes. Diabetes Care. 2009;32(12):e148.
68. Monami M, Cresci B, Colombini A et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2008;31(2):199-203.
69. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-5.
70. Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract. 2000;6(6):442-6.
71. Liu F, Lu JX, Tang JL et al. Relationship of plasma creatinine and lactic acid in type 2 diabetic patients without renal dysfunction. Chin Med J (Engl). 2009;122(21):2547-53.
72. Li Q, Liu F, Zheng TS et al. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin. 2010;31(2):184-90.
73. Lodovici M, Bigagli E, Luceri C et al. Gender-related drug effect on several markers of oxidation stress in diabetes patients with and without complications. Eur J Pharmacol. 2015;766:86-90.
74. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-43.
75. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474-6.
76. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol. 2011;7(6):727-36.
77. Gough SC, Belda-Iniesta C, Poole C et al. Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther. 2011;28 Suppl 5:1-18.
78. Rabi DM, Khan N, Vallee M et al. Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol. 2008;24(6):491-6.
79. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006;97(4):567-70.
80. De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: metaanalysis of randomised controlled trials. Bmj. 2009;339:b4531.
81. Solini A, Penno G, Bonora E et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012;35(1):143-9.
82. de Boer IH, Rue TC, Hall YN et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. Jama. 2011;305(24):2532-9.
83. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens. 2001;10(2):219-25.
84. Franconi F, Campesi I, Occhioni S, Tonolo G. Sex-gender differences in diabetes vascular complications and treatment. Endocr Metab Immune Disord Drug Targets. 2012;12(2):179-96.
85. Thoenes M, Neuberger HR, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24(5):336-44.
86. Tonolo G, Cherchi S. Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2014;7:107-15.
87. Schultz CJ, Konopelska-Bahu T, Dalton RN et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care. 1999;22(3):495-502.
88. Maric C. Sex, diabetes and the kidney. Am J Physiol Renal Physiol. 2009;296(4):F680-8.
89. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis. 2006;47(2):223-32.
90. Maric C, Hall JE. Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol. 2011;170:28-35.
91. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. Jama. 2003;290(2):199-206.
92. Diamond-Stanic MK, You YH, Sharma K. Sugar, sex, and TGFbeta in diabetic nephropathy. Semin Nephrol. 2012;32(3):261-8.
93. Lin Y, Nakachi K, Ito Y et al. Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers. 2009;27(1):23-8.
94. Elliot SJ, Berho M, Korach K et al. Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney Int. 2007;72(4):464-72.
95. Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288(2):F399-405.
96. Catanuto P, Doublier S, Lupia E et al. 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int. 2009;75(11):1194-201.
97. Dixon A, Maric C. 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol Renal Physiol. 2007;293(5):F1678-90.
98. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol. 2007;27(2):153-60.
99. Yanes LL, Sartori-Valinotti JC, Reckelhoff JF. Sex steroids and renal disease: lessons from animal studies. Hypertension. 2008;51(4):976-81.
100. Harjutsalo V, Maric C, Forsblom C et al. Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia. 2011;54(8):1992-9.
101. Ahmed SB, Hovind P, Parving HH et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care. 2005;28(8):1988-94.
102. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85(4):447-52.
103. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama. 1998;280(7):605-13.
104. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Jama. 2007;297(13):1465-77.
105. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-602.
106. Maric C, Forsblom C, Thorn L, Waden J, Groop PH. Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids. 2010;75(11):772-8.
107. Prabhu A, Xu Q, Manigrasso MB et al. Expression of aromatase, androgen and estrogen receptors in peripheral target tissues in diabetes. Steroids. 2010;75(11):779-87.
108. Gu HF, Alvarsson A, Efendic S, Brismar K. SOX2 has genderspecific genetic effects on diabetic nephropathy in samples from patients with type 1 diabetes mellitus in the GoKinD study. Gend Med. 2009;6(4):555-64.
109. Freire MB, Ji L, Onuma T et al. Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension. 1998;31(4):896-9.
110. Pettersson-Fernholm K, Frojdo S, Fagerudd J et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int. 2006;69(10):1880-4.
111. Gnudi L, Goldsmith D. Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep. 2010;2.
112. Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int. 2005;68(4):1722-8.
113. Penno G, Solini A, Bonora E et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 2011;29(9):1802-9.
114. Kajiwara A, Miyagawa H, Saruwatari J et al. Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: a clinic-based retrospective longitudinal study. Diabetes Res Clin Pract. 2014;103(3):e7-10.
115. Institute of Medicine. Women’s Health Research: Progress, Pitfalls, and Promise. 2010.
116. Mahonen MS, McElduff P, Dobson AJ, Kuulasmaa KA, Evans AE. Current smoking and the risk of non-fatal myocardial infarction in the WHO MONICA Project populations. Tob Control. 2004;13(3):244-50.
117. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care. 1978;1(3):146-9.
118. Orth SR. Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol. 2004;15 Suppl 1:S58-63.
119. Lajous M, Tondeur L, Fagherazzi G et al. Childhood and adult secondhand smoke and type 2 diabetes in women. Diabetes Care. 2013;36(9):2720-5.
120. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism. 2011;60(10):1456-64.
121. Couper JJ, Staples AJ, Cocciolone R et al. Relationship of smoking and albuminuria in children with insulin-dependent diabetes. Diabet Med. 1994;11(7):666-9.
122. Borch-Johnsen K, Nissen H, Henriksen E et al. The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications. Diabet Med. 1987;4(3):201-10.
123. Mackin P, Macleod JM, New JP, Marshall SM. Renal function in long-duration type I diabetes. Diabetes Care. 1996;19(3):249-51.
124. Unuigbe EI, Omeife H, Edema T, Ukoli FA. Microalbuminuria and associated factors in newly diagnosed diabetics. Niger Postgrad Med J. 2001;8(4):187-92.
125. Chuahirun T, Khanna A, Kimball K, Wesson DE. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis. 2003;41(1):13-21.
126. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med. 1996;2(1):41-5.
127. Perna A, Iordache BE, Bettinaglio P et al. DD ACE genotype and smoking cluster with high-normal albuminuria: A cross-sectional analysis in 1209 normo-albuminuric type 2 diabetics enrolled in the BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) [Abstract]. J Am Soc Nephrol. 2001:154A.
128. Campesi I, Carru C, Zinellu A et al. Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. Am J Transl Res. 2013;5(5):497-509.
129. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7(1):35-43.
130. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32-5.
131. Zhang X, Saaddine JB, Chou CF et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. Jama. 2010;304(6):649-56.
132. Schanzlin DJ, Jay WH, Fritz KJ, Tripathi RC, Gonen B. Hemoglobin A1 and diabetic retinopathy. Am J Ophthalmol. 1979;88(6):1032-8.
133. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (author’s transl)]. Diabete Metab. 1977;3(2):97-107.
134. Constable IJ, Knuiman MW, Welborn TA et al. Assessing the risk of diabetic retinopathy. Am J Ophthalmol. 1984;97(1):53-61.
135. West KM, Ahuja MM, Bennett PH et al. Interrelationships of microangiopathy, plasma glucose and other risk factors in 3583 diabetic patients: a multinational study. Diabetologia. 1982;22(6):412-20.
136. Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M. Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population--the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med. 2008;25(5):536-42.
137. Rani PK, Raman R, Chandrakantan A et al. Risk factors for diabetic retinopathy in self-reported rural population with diabetes. J Postgrad Med. 2009;55(2):92-6.
138. Kashani AH, Zimmer-Galler IE, Shah SM et al. Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol. 2010;149(3):496-502e1.
139. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-64.
140. Jervell J, Moe N, Skjaeraasen J, Blystad W, Egge K. Diabetes mellitus and pregnancy--management and results at Rikshospitalet, Oslo, 1970-1977. Diabetologia. 1979;16(3):151-5.
141. Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol. 1982;93(6):745-56.
142. Ogawa K, Okamoto N, Saito Y et al. A case of diabetic retinopathy that progressed with sex hormone administration. Folia Ophthalmol Jpn. 1993;44:1338-42.
143. Campesi I, Sanna M, Zinellu A et al. Oral contraceptives modify DNA methylation and monocyte-derived macrophage function. Biol Sex Differ. 2012;3:4.
144. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-24.
145. Albers JW, Brown MB, Sima AA, Greene DA. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology. 1996;46(1):85-91.
146. Booya F, Bandarian F, Larijani B et al. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol. 2005;5:24.
147. Brown MJ, Bird SJ, Watling S et al. Natural proression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care. 2004;27(5):1153-9.
148. Dyck PJ, Litchy WJ, Lehman KA et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45(6):1115-21.
149. Pop-Busui R, Lu J, Lopes N, Jones TL. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst. 2009;14(1):1-13.
150. Lombardo FL, Maggini M, De Bellis A, Seghieri G, Anichini R. Lower extremity amputations in persons with and without diabetes in Italy: 2001-2010. PLoS One. 2014;9(1):e86405.
151. Peek ME. Gender differences in diabetes-related lower extremity amputations. Clin Orthop Relat Res. 2011;469(7):1951-5.
152. Prompers L, Schaper N, Apelqvist J et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51(5):747-55.
153. Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications. 2008;22(2):83-7.
154. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab. 2005;90(10):5896-903.
155. Zoppini G, Cacciatori V, Raimondo D et al. Prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 Diabetes: The Verona newly diagnosed type 2 diabetes study (VNDS). Diabetes Care. 2015;38(8):1487-93.
156. Griffin M, Lee HW, Zhao L, Eghbali-Webb M. Gender-related differences in proliferative response of cardiac fibroblasts to hypoxia: effects of estrogen. Mol Cell Biochem. 2000;215(1-2):21-30.
157. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest. 2000;106(4):589-97.
158. Peng S, Yu Y, Hao K et al. Heart rate-corrected QT interval duration is significantly associated with blood pressure in Chinese hypertensives. J Electrocardiol. 2006;39(2):206-10.
159. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. 2004;53(2):434-40.
160. Rana BS, Lim PO, Naas AA et al. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart. 2005;91(1):44-50.
161. Giunti S, Bruno G, Lillaz E et al. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2007;30(8):2057-63.
162. Seghieri C, Francesconi P, Cipriani S et al. Gender effect on the relation between diabetes and hospitalization for heart failure. Exp Clin Endocrinol Diabetes. 2012;120(1):51-5.
163. Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-8.
164. Kempler P, Amarenco G, Freeman R et al. Gastrointestinal autonomic neuropathy, erectile-, bladder-and sudomotor dysfunction in patients with diabetes mellitus: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011.
165. Fedele D, Coscelli C, Santeusanio F et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care. 1998;21(11):1973-7.
166. Kalra B, Kalra S, Bajaj S. Vulvodynia: An unrecognized diabetic neuropathic syndrome. Indian J Endocrinol Metab. 2013;17(5):787-9.